Explore the Agenda
6:45 am Check In, Morning Coffee & Light Refreshments
7:45 am Chair’s Opening Remarks
Unlocking Innovative XDC Design Excellence to Improve Efficacy & Tolerability to Widen the Therapeutic Index
8:00 am Precision Delivery of Therapeutics with Antibodies Through Biology, Chemistry & AI
- How antibodies enable more precise delivery of therapeutic payloads for oncology and beyond to selected tissues and cell types
- Outlining the biological and chemical challenges that determine whether targeted delivery translates into meaningful therapeutic benefit
- How AI is accelerating the design and optimisation of next-generation antibody-enabled delivery systems
8:30 am Evaluating Phase & Product Appropriate Bioconjugate Development
- Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
- Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing mechanisms of action and molecular structures
- Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates
9:00 am Panel Discussion: Trailblazing Next-Generation of ADCs from XDCs to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinical Validation
- Debating the optimal chemical and biological properties of next-generation payload and linker combinations
- Exploring the novelty of dual-payload ADCs and their potential to overcome resistance and improve safety profiles compared to traditional ADCs
- Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
9:45 am Session Reserved for SK Pharmteco
10:15 am Morning Break, Networking & Poster Session
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
Discovery Track
Exploring Novel Antibody Engineering to Enhance ADC Performance
11:15 am Discovery & Development of Click-to Release ADCs With Enhanced Therapeutic Potential
Vice President & Head of Preclinical Research, Tagworks Pharmaceuticals
- Using the learnings from first in class clinical stage click-cleavable ADC TGW101 against TAG72 in next-generation designs to further expand the ADC target universe into the non internalizing target space
- Highlighting how the Click-to-Release linker system affords a highly differentiated safety and efficacy profile across several payload classes
- Discussing protein design considerations and functional characterisation of our discovery phase ADCs
11:45 am Session Reserved for Vector Laboratories
12:15 pm New Insights & Applications of Antibody-Drug Conjugation by Disulfide Re-Bridging
Professor of Chemistry, University College London
- Disulfide re-bridging is a leading method for the construction of next-generation site-selective ADCs, and the resultant ADCs are in advanced clinical trials
- Sharing a detailed understanding of the processes involved in re-bridging has been lacking to date, and has led to difficulty in identifying optimal reagents and protocols to maximise homogeneity
- Revealing recent data which shines a new light on these conjugates, provides new design principles for optimised conjugates, whilst also discussing new ADC opportunities enabled by disulfide re-bridging strategies
12:45 pm RoundTable Discussion: Outlining Considerations & Rational Design Strategy for Profiling & Designing Novel ADC Conjugate Payloads
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:15 pm Lunch & Learn Session Presentation Hosted By Schott Pharma
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
3 Sessions
Translating ADC Discoveries into Translational Therapies with Biological Efficacy & Pharmacology
2:15 pm Unlocking the Pre-Clinical Pharmacology of a Surface Receptor Targeting ADC
Senior Principal Scientist – Oncology Research Unit, GlaxoSmithKline
- Summarising past data and clinical outcomes for ADCs surrounding a novel surface-receptor target
- Presenting a novel receptor-targeting ADC asset
- Demonstrating its pre-clinical pharmacology
2:45 pm Round Table Discussion: From In Vitro Screening to In Vivo Proof of Concept – Re-Evaluating Payload Evaluation Criteria & Learning from Failed Novel Payloads to Combat ADC Potency & Stability
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
3:15 pm Afternoon Break & Networking
From First-in-Class to Best-in-Class: Advancing the Next Wave of ADCs into the Clinic in Areas of Unmet Need
3:45 pm Showcasing the Pre-Clinical to Phase I Clinical Development of DS3790 – A Novel CD37 Target & First DXd ADC in Haematology
- DS3790 is an investigational, potential first-in-class CD37 directed ADC
- Showcasing designs with DXd ADC technology, DS3790 is comprised of a humanized anti-CD37 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (exatecan derivative, DXd) via tetrapeptide-based cleavable linkers
4:15 pm Spotlighting Sofetabart Mipitecan, an ADC-Targeting Folate Receptor Alpha, in High Grade Ovarian Cancer
- Unlocking the preclinical and PSAR technology of Sofe-M
- Highlighting results from the first-in-human phase 1 study
- Advancing model informed drug development to inform Phase 3 dose
4:45 pm STRO-004 Clinical Learnings: How ADC Design Shapes Safety & Efficacy
- Tracing STRO-004’s development from antibody engineering and linker–payload design to its potential clinical differentiation among ADC therapies
- Presenting new Phase I safety and pharmacokinetic data for tissue factor–targeted STRO-004, including translation from cynomolgus monkey studies and implications for therapeutic index
- Examining the design rationale and development of dual-payload ADCs to address resistance to single-payload therapies.